Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations

被引：278

作者：

Abdullah, Mardiaty Iryani ^{[1
,5
]}

Junit, Sarni Mat ^{[1
]}

Ng, Khoon Leong ^{[2
]}

Jayapalan, Jaime Jacqueline ^{[3
]}

Karikalan, Barani ^{[4
]}

Hashim, Onn Haji ^{[1
,3
]}

机构：

[1] Univ Malaya, Fac Med, Dept Mol Med, Kuala Lumpur 50603, Malaysia

[2] Univ Malaya, Fac Med, Dept Surg, Kuala Lumpur 50603, Malaysia

[3] Univ Malaya, Ctr Prote Res, Fac Med, Kuala Lumpur 50603, Malaysia

[4] Perdana Univ, Jalan MAEPS Perdana, Serdang 43400, Selangor, Malaysia

[5] Int Islamic Univ Malaysia, Kulliyyah Allied Hlth Sci, Dept Biomed Sci, Kuantan 25200, Pahang, Malaysia

来源：

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES | 2019年 / 16卷 / 03期

关键词：

papillary thyroid cancer; molecular alteration; genetic signature; biomarker; diagnostics; FINE-NEEDLE-ASPIRATION; BRAF V600E MUTATION; ONCOGENE REARRANGEMENTS; EXPRESSION PROFILES; CLINICAL-FEATURES; TUMOR PROGRESSION; NUCLEAR FEATURES; GROWTH-FACTOR; UP-REGULATION; CARCINOMA;

D O I：

10.7150/ijms.29935

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Papillary thyroid cancer (PTC) is the most prevalent form of malignancy among all cancers of the thyroid. It is also one of the few cancers with a rapidly increasing incidence. PTC is usually contained within the thyroid gland and generally biologically indolent. Prognosis of the cancer is excellent, with less than 2% mortality at 5 years. However, more than 25% of patients with PTC developed a recurrence during a long term follow-up. The present article provides an updated condensed overview of PTC, which focuses mainly on the molecular alterations involved and recent biomarker investigations.

引用

页码：450 / 460

页数：11

共 123 条

[1] Tissue and serum samples of patients with papillary thyroid cancer with and without benign background demonstrate different altered expression of proteins [J].